{"id":832632,"date":"2025-04-01T16:11:48","date_gmt":"2025-04-01T20:11:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/"},"modified":"2025-04-01T16:11:48","modified_gmt":"2025-04-01T20:11:48","slug":"revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/","title":{"rendered":"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting"},"content":{"rendered":"
\n

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 \u2013 30, 2025.<\/p>\n

The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation.<\/p>\n

Details of the abstracts are listed below:<\/p>\n

\n
\n Revolution Medicines Oral Presentations: <\/u>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n
Title:<\/td>\n\n Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a Phase 1 study in advanced solid tumors<\/a>\n <\/td>\n<\/tr>\n
Presenter:<\/td>\nKathryn Arbour, M.D., Memorial Sloan Kettering Cancer Center<\/td>\n<\/tr>\n
Abstract Number:<\/td>\nCT019<\/td>\n<\/tr>\n
Session:<\/td>\nNew Frontiers in Precision Oncology<\/td>\n<\/tr>\n
Date\/Time:<\/td>\nApril 27; 5:00 p.m. \u2013 5:15 p.m. CST<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n\n\n\n
Title:<\/td>\n\n Discovery of RMC-5127, an oral, RAS(ON) G12V-selective, noncovalent, tri-complex inhibitor<\/a>\n <\/td>\n<\/tr>\n
Presenter:<\/td>\nAnne Edwards, Ph.D.<\/td>\n<\/tr>\n
Abstract Number:<\/td>\nND06<\/td>\n<\/tr>\n
Session:<\/td>\nNew Drugs on the Horizon: Part 2<\/td>\n<\/tr>\n
Date\/Time:<\/td>\nApril 27; 3:25 p.m. \u2013 3:40 p.m. CST<\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n
\n Revolution Medicines Poster Presentations:<\/u>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n
Title:<\/td>\n\n Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)<\/a>\n <\/td>\n<\/tr>\n
Presenter:<\/td>\nJia Luo, M.D., Dana-Farber Cancer Institute<\/td>\n<\/tr>\n
Abstract Number:<\/td>\nLB218<\/td>\n<\/tr>\n
Session:<\/td>\nLate-Breaking Research: Clinical Research 1<\/td>\n<\/tr>\n
Date\/Time:<\/td>\nApril 28; 2:00 p.m. \u2013 5:00 p.m. CST<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n\n\n
Title:<\/td>\n\n Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies<\/a>\n <\/td>\n<\/tr>\n
Presenter:<\/td>\nMallika Singh, Ph.D.<\/td>\n<\/tr>\n
Abstract Number:<\/td>\nLB281<\/td>\n<\/tr>\n
Session:<\/td>\nLate-Breaking Research: Experimental and Molecular Therapeutics 3<\/td>\n<\/tr>\n
Date\/Time:<\/td>\nApril 29; 9:00 a.m. \u2013 12:00 p.m. CST<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n\n\n\n
Title:<\/td>\n\n Combination of RAS(ON) mutant-selective and multi-selective inhibitors sensitizes immune-refractory, RAS-driven preclinical models to immunotherapy<\/a>\n <\/td>\n<\/tr>\n
Presenter:<\/td>\nMariela Moreno Ayala, Ph.D.<\/td>\n<\/tr>\n
Abstract Number:<\/td>\n6046<\/td>\n<\/tr>\n
Session:<\/td>\nAdaptive Immunity in Tumors \/ Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor Immunity<\/td>\n<\/tr>\n
Date\/Time:<\/td>\nApril 29; 2:00 p.m. \u2013 5:00 p.m. CST<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n
\n Collaborator Presentations <\/u>
\n <\/strong>\n <\/p>\n\n\n\n\n\n\n
Title:<\/td>\n\n Distinct regulation of Cyclin D mediates heterogenous response to RAS inhibition in colorectal cancer models<\/a>\n <\/td>\n<\/tr>\n
Presenter:<\/td>\nPhilip Choi, M.D., Ph.D., Memorial Sloan Kettering Cancer Center<\/td>\n<\/tr>\n
Abstract Number:<\/td>\nLB293<\/td>\n<\/tr>\n
Session:<\/td>\nLate-Breaking Research: Experimental and Molecular Therapeutics 3<\/td>\n<\/tr>\n
Date\/Time:<\/td>\nApril 29; 9:00 a.m. \u2013 12:00 p.m. CST<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n\n\n
Title:<\/td>\n\n Combining RAS(ON) G12C-selective and RAS(ON) multi-selective inhibitors overcomes sotorasib resistance driven by KRAS G12C amplification or NRAS G13R mutation<\/a>\n <\/td>\n<\/tr>\n
Presenter:<\/td>\nHitendra Singh Solanki, Ph.D., Moffitt Cancer Center<\/td>\n<\/tr>\n
Abstract Number:<\/td>\n5512<\/td>\n<\/tr>\n
Session:<\/td>\nDrug Resistance in Molecular Targeted Therapies 3<\/td>\n<\/tr>\n
Date\/Time:<\/td>\nApril 29; 2:00 p.m. \u2013 5:00 p.m. CST<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n\n\n
Title:<\/td>\n\n A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in preclinical models of PDAC<\/a>\n <\/td>\n<\/tr>\n
Presenter:<\/td>\nCaroline Broderick, Ph.D., Memorial Sloan Kettering Cancer Center<\/td>\n<\/tr>\n
Abstract Number:<\/td>\n5336<\/td>\n<\/tr>\n
Session:<\/td>\nCDK Inhibitors<\/td>\n<\/tr>\n
Date\/Time:<\/td>\nApril 29; 2:00 p.m. \u2013 5:00 p.m. CST<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n\n\n
Title:<\/td>\n\n Preclinical evaluation of RMC-7977, a multi-selective RAS(ON) inhibitor, as a therapeutic strategy for KRAS-mutant cholangiocarcinoma<\/a>\n <\/td>\n<\/tr>\n
Presenter:<\/td>\nJingjing Jiang, Ph.D.<\/td>\n<\/tr>\n
Abstract Number:<\/td>\n5691<\/td>\n<\/tr>\n
Session:<\/td>\nOncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 2<\/td>\n<\/tr>\n
Date\/Time:<\/td>\nApril 29; 2:00 p.m. \u2013 5:00 p.m. CST<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n\n\n
Title:<\/td>\n\n Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer<\/a>\n <\/td>\n<\/tr>\n
Presenter:<\/td>\nJoshua H. Choe, Dana-Farber Cancer Institute<\/td>\n<\/tr>\n
Abstract Number:<\/td>\n5507<\/td>\n<\/tr>\n
Session:<\/td>\nDrug Resistance in Molecular Targeted Therapies 3<\/td>\n<\/tr>\n
Date\/Time:<\/td>\nApril 29; 2:00 p.m. \u2013 5:00 p.m. CST<\/td>\n<\/tr>\n<\/table>\n

\n \n <\/p>\n\n\n\n\n\n\n\n
Title:<\/td>\n\n T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC<\/a>\n <\/td>\n<\/tr>\n
Presenter:<\/td>\nMargo I. Orlen, Penn Medicine<\/td>\n<\/tr>\n
Abstract Number:<\/td>\n6405<\/td>\n<\/tr>\n
Session:<\/td>\nCheckpoints and Modulators of Tumor Microenvironment<\/td>\n<\/tr>\n
Date\/Time:<\/td>\nApril 29; 3:25 p.m. \u2013 3:40 p.m. CST<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About Revolution Medicines, Inc.
<\/strong>Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company\u2019s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company\u2019s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company\u2019s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit\u00a0www.revmed.com<\/a>\u00a0and follow us on\u00a0LinkedIn<\/a>.<\/p>\n

\n Revolution Medicines Media & Investor Contact:<\/strong>
\n
media@revmed.com
investors@revmed.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 \u2013 30, 2025. The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation. Details of the abstracts are listed below: Revolution Medicines Oral Presentations: Title: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer … <\/p>\n

Continue reading “Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-832632","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRevolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 \u2013 30, 2025. The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation. Details of the abstracts are listed below: Revolution Medicines Oral Presentations: Title: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer … Continue reading "Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-01T20:11:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTE1MyM2ODQ0ODcwIzIxOTQwMzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting\",\"datePublished\":\"2025-04-01T20:11:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/\"},\"wordCount\":756,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTE1MyM2ODQ0ODcwIzIxOTQwMzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/\",\"name\":\"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTE1MyM2ODQ0ODcwIzIxOTQwMzQ=\",\"datePublished\":\"2025-04-01T20:11:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTE1MyM2ODQ0ODcwIzIxOTQwMzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNTE1MyM2ODQ0ODcwIzIxOTQwMzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk","og_description":"REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 \u2013 30, 2025. The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation. Details of the abstracts are listed below: Revolution Medicines Oral Presentations: Title: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer … Continue reading \"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-01T20:11:48+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTE1MyM2ODQ0ODcwIzIxOTQwMzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting","datePublished":"2025-04-01T20:11:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/"},"wordCount":756,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTE1MyM2ODQ0ODcwIzIxOTQwMzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/","name":"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTE1MyM2ODQ0ODcwIzIxOTQwMzQ=","datePublished":"2025-04-01T20:11:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTE1MyM2ODQ0ODcwIzIxOTQwMzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNTE1MyM2ODQ0ODcwIzIxOTQwMzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/revolution-medicines-to-deliver-multiple-presentations-at-the-2025-american-association-for-cancer-research-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=832632"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832632\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=832632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=832632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=832632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}